Traws Pharma, Inc. (TRAW) is a Healthcare stock trading at $0.57 (as of 2026-08-04), with a market capitalization of $8.57M and a trailing P/E of 0.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral therapies for respiratory viral diseases and cancer, including investigational candidates for COVID-19, pandemic influenza, and a multi-kinase CDK4/6 inhibitor in Phase 1/2.
Because Traws Pharma is focused on developing investigational drug candidates (TRX01 for COVID-19, TRX100 for pandemic influenza, and narazaciclib for cancer), its profit model depends on whether these development programs can generate future value, rather than on selling current approved products.
Business quality (Solid): Clear therapeutic pipeline focus (viral disease resistance and a CDK4/6 inhibitor), but the provided facts also show no current revenue and a very large operating loss, which underscores development and execution risk.
| Price | $0.57 |
| Market Cap | $8.57M |
| P/E Ratio | 0.1 |
| EV / EBITDA | 0.0 |
| Price / Book | 5.07 |
| Price / Sales | 1.05 |
| FCF Yield | -76.9% |
| Revenue (TTM) | $2.79M |
| Net Margin | 328.7% |
| Revenue Growth (YoY) | 1134.5% |
| EPS Growth (YoY) | -102.4% |
| FCF Growth (YoY) | -37.9% |
| Altman Z-Score | -89.58 (distress) |
| Stock P/E | 0.1 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -99.8% |
| vs Industry | -99.7% |
| Top Institutional Holder | ADAGE CAPITAL PARTNERS GP, L.L.C. ($1.34M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Iain D. Dukes |
| Employees | 6 |
| Country | US |
| IPO Date | 2013-07-25 |
Data as of 2026-08-04.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.